We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
- Authors
Naruto, Kensuke; Kawaoka, Tomokazu; Amioka, Kei; Ogawa, Yutaro; Chihiro, Kikukawa; Yoshikawa, Yuki; Ando, Yuwa; Suehiro, Yosuke; Kosaka, Yumi; Uchikawa, Shinsuke; Kodama, Kenichiro; Morio, Kei; Fujino, Hatsue; Murakami, Eisuke; Nakahara, Takashi; Yamauchi, Masami; Tsuge, Masataka; Hiramatsu, Akira; Fukuhara, Takayuki; Takaki, Shintaro
- Abstract
Introduction: This study compared clinical outcomes of 2nd- and 3rd-line regorafenib in patients with unresectable hepatocellular carcinoma. Methods: In this retrospective cohort study, 48 patients were treated with regorafenib for unresectable hepatocellular carcinoma. Thirty-five and 13 patients were initiated on 2nd- and 3rd-line therapy, respectively. We assessed the responses to and safety of the therapy. Results: There were no statistically significant differences in clinical characteristics at the start of 2nd- or 3rd-line regorafenib therapy. The overall response rate of 2nd- and 3rd-line regorafenib was 20 and 8%, respectively. The disease control rate was 57 and 54%, respectively. Median overall survival (mOS) from the start of 2nd-line regorafenib was 17.5 months. mOS from the start of 3rd-line regorafenib was not obtained. Median progression-free survival of 2nd- and 3rd-line regorafenib was 4.9 and 2.3 months, respectively. mOS from 1st-line therapy with tyrosine kinase inhibitor plus sorafenib-regorafenib-lenvatinib was 29.5 months; that with lenvatinib-sorafenib-regorafenib was not obtained. Patients on 3rd-line therapy tended to have better Child-Pugh scores and tumor factors at the start of 1st-line therapy than other patients. Conclusion: Patients on 2nd- and 3rd-line regorafenib showed favorable responses. Good Child-Pugh scores and tumor factors may be associated with a better response rate and OS.
- Subjects
THERAPEUTIC use of antineoplastic agents; PROTEIN kinase inhibitors; RETROSPECTIVE studies; TREATMENT effectiveness; PROTEIN-tyrosine kinase inhibitors; SURVIVAL analysis (Biometry); DESCRIPTIVE statistics; SORAFENIB; HEPATOCELLULAR carcinoma; LONGITUDINAL method; PATIENT safety; EVALUATION
- Publication
Oncology, 2021, Vol 99, Issue 8, p491
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000515280